CWD vs GSK · rev $20.1M vs P/E 13, $103.31B cap
CaliberCos Inc. Class A Common Stock (CWD) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
CaliberCos Inc. Class A Common Stock (CWD) is a asset management company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported CWD revenue for 2025-12-31 was $20.1M. Net income was -$21.8M. Revenue was down 60.7% from 2024-12-31 to 2025-12-31. CWD currently screens at market cap $4.5M.
GSK does not have a complete income-statement cache yet.
CWD currently screens at market cap $4.5M. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the CWD and GSK stock pages for the full models.
Not investment advice.